Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation fo… Read more
Evelo Biosciences Inc (EVLO) - Net Assets
Latest net assets as of September 2023: $-26.71 Million USD
Based on the latest financial reports, Evelo Biosciences Inc (EVLO) has net assets worth $-26.71 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.63 Million) and total liabilities ($47.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-26.71 Million |
| % of Total Assets | -129.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.65% |
| 10-Year Change | N/A |
| Growth Volatility | 231.03 |
Evelo Biosciences Inc - Net Assets Trend (2016–2022)
This chart illustrates how Evelo Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Evelo Biosciences Inc (2016–2022)
The table below shows the annual net assets of Evelo Biosciences Inc from 2016 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-4.99 Million | -157.60% |
| 2021-12-31 | $8.67 Million | -71.57% |
| 2020-12-31 | $30.48 Million | -49.36% |
| 2019-12-31 | $60.20 Million | -56.04% |
| 2018-12-31 | $136.95 Million | +365.77% |
| 2017-12-31 | $29.40 Million | +432.08% |
| 2016-12-31 | $5.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evelo Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50088100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $111.00K | % |
| Other Components | $524.12 Million | % |
| Total Equity | $-4.99 Million | 100.00% |
Evelo Biosciences Inc Competitors by Market Cap
The table below lists competitors of Evelo Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IMPIANTI S.P.A.
F:F67
|
$7.60K |
|
Staige One AG
XETRA:SPC
|
$7.61K |
|
BSLI3F
SA:BSLI3F
|
$7.61K |
|
Igiant Optics Co., Ltd.
TWO:6915
|
$7.62K |
|
Traccom Inc
PINK:TRCC
|
$7.59K |
|
METALS X (FG5.SG)
STU:FG5
|
$7.58K |
|
CHINA UNICOM (HK) - Dusseldorf Stock Exchang
DU:XCI
|
$7.57K |
|
BMGB4F
SA:BMGB4F
|
$7.55K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evelo Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 8,667,000 to -4,992,000, a change of -13,659,000 (-157.6%).
- Net loss of 114,527,000 reduced equity.
- New share issuances of 84,544,000 increased equity.
- Other factors increased equity by 16,324,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-114.53 Million | -2294.21% |
| Share Issuances | $84.54 Million | +1693.59% |
| Other Changes | $16.32 Million | +327.0% |
| Total Change | $- | -157.60% |
Book Value vs Market Value Analysis
This analysis compares Evelo Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $38.99 | $0.00 | x |
| 2017-12-31 | $156.78 | $0.00 | x |
| 2018-12-31 | $125.23 | $0.00 | x |
| 2019-12-31 | $37.59 | $0.00 | x |
| 2020-12-31 | $15.44 | $0.00 | x |
| 2021-12-31 | $3.28 | $0.00 | x |
| 2022-12-31 | $-1.15 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evelo Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-319.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -241.26% | 0.00% | 0.00x | 3.36x | $-13.88 Million |
| 2017 | -95.39% | 0.00% | 0.00x | 1.49x | $-30.99 Million |
| 2018 | -39.32% | 0.00% | 0.00x | 1.17x | $-67.55 Million |
| 2019 | -142.30% | 0.00% | 0.00x | 1.51x | $-91.68 Million |
| 2020 | -307.25% | 0.00% | 0.00x | 2.97x | $-96.71 Million |
| 2021 | -1409.67% | 0.00% | 0.00x | 10.14x | $-123.04 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-114.03 Million |
Industry Comparison
This section compares Evelo Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evelo Biosciences Inc (EVLO) | $-26.71 Million | -241.26% | N/A | $7.59K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |